R.I. Kunafina1, O.N. Lipatov1,2, I.V. Asfandiyarova1, A.Kh. Muzafarov1, A.I. Iskhakova1, E.I. Kankumasheva1, E.R. Siraeva1, R.K. Fazlinurov1, N.O. Yuldasheva1
1Republican Clinical Oncology Dispensary, Ufa
2Bashkir State Medical University, Ufa
Kunafina Regina I. ― Head of the Department of antitumor drug therapy №1 of the Republican Clinical Oncology Dispensary
73/1 Oktyabrya Ave., Ufa, 450054, Russian Federation, e-mail: kunafinareg2007@yandex.ru, ORCID ID: 0000-0002-6403-5945
Abstract. Hodgkin’s lymphoma (LH) is a highly treatable disease. The use of modern therapy makes it possible to achieve complete remission from 80 to 95% of patients with primary LH, while the 5-year survival rate exceeds 80-90%. Nevertheless, 5-30% of LH patients have relapses or a primary refractory course of the disease. Therapy with inhibitors of control response points in the absence of a response to line 2 in the case of a chemoresistant form of Hodgkin’s lymphoma allows for long-term and persistent remission. Immunotherapy allows you to increase the time before switching to a new line of treatment, thereby increasing the overall survival of patients with resistant forms of LH.
The article describes the result of the successful use of nivolumab and pembrolizumab in a patient with a refractory, chemoresistant form of LH who has a long history of treatment (21 years)
Key words: Hodgkin lymphoma, chemotherapy, anti-PD1 therapy.